Influence of CYP2D6 Gene Polymorphisms on the Pharmacokinetics of Aripiprazole in Healthy Chinese Subjects

• Published in: Pharmacogenomics Vol. 22; no. 4; pp. 213 - 223
• Main Authors: Zhang, Xiaodan, Liu, Chengquan, Zhou, Shuang, Xie, Ran, He, Xu, Wang, Zhiqi, Yi, Honghong, Shu, You, Wang, Zining, Hu, Kun, Ma, Lingyue, Cui, Yimin, Zhao, Xia, Xiang, Jin
• Format: Journal Article
• Language: English
• Published: England 01.03.2021
• Subjects: pharmacokinetics; aripiprazole; CYP2D6 gene polymorphisms; consistency evaluation of generic drugs; evaluation study of bioequivalence
• ISSN: 1462-2416; 1744-8042; 1744-8042
• DOI: 10.2217/pgs-2020-0134

Pharmacogenetics study was added into 2 bioequivalence trials of aripiprazole. The correlation between polymorphisms and aripiprazole pharmacokinetics (PK) was analyzed. A total of 140 subjects were included. A total of 26 gene alleles were detected. The plasma concentration of aripiprazole was measured by liquid chromatography-tandem mass spectrometry. was used to analyze the correlation between polymorphisms and aripiprazole PK parameters. All of the four PK parameters were significantly influenced by and . t and area under the concentration-time curve exhibited significant difference between extensive metabolizers and intermediate metabolizers. Aripiprazole PK was greatly influenced by . Attention should be paid to the possible dose adjustment for intermediate metabolizer population when the drug is used in Chinese patients.